How much funding has Triveni Bio raised?

Triveni Bio has raised $272.0M in total funding, most recently a Venture Round.

Who are Triveni Bio's investors?

Triveni Bio's investors include Goldman Sachs Alternatives, Atlas Venture, Cormorant Asset Management, Fidelity Management, OrbiMed, Viking Global.

Where is Triveni Bio headquartered?

Triveni Bio is headquartered in United States.

What industry is Triveni Bio in?

Triveni Bio operates in Biotech, Healthcare.

How many employees does Triveni Bio have?

Triveni Bio has 11-50 employees.

Triveni Bio

Breaking Efficacy Ceilings

United States · $272.0M raised

Biotech

Healthcare

Employees: 11–50
Business Model: B2B
Website: triveni.bio

Total Funding: $272.0M
Last Round: $65.0M Venture RoundJun 2026
Rounds: 3

About

Triveni Bio is a clinical-stage biotech company taking a genetics-informed approach and leveraging advanced antibody engineering to build first-in-class therapeutics for immune and inflammatory diseases. The company combines human genetics insights with novel antibody engineering to address root causes of conditions like atopic dermatitis. It is backed by Atlas Venture and headquartered in the Boston/Cambridge area.

Summary

Triveni Bio is a Biotech company based in United States. It has raised $272.0M in total across 3 rounds, most recently a $65.0M Venture Round round in Jun 2026. Investors include Goldman Sachs Alternatives, Atlas Venture and Cormorant Asset Management.